Skip to main content
Saudi Journal of Medicine & Medical Sciences logoLink to Saudi Journal of Medicine & Medical Sciences
. 2025 Jan 11;13(1):32–38. doi: 10.4103/sjmms.sjmms_136_24

Clinical Profile and Antibiotic Susceptibility Patterns of Cronobacter sakazakii in the Northern Region of Oman

Mohan Bilikallahalli Sannathimmappa 1,, Vinod Nambiar 1, Osama Mohammed Salih Adnan Al-Alawi 1, Mouge Mohammad Salah Al-Fragi 1, Isra Mohammed Ali Al Mani 1, Zahra Merza Ahmed Hasan Ahmed Madan 1, Salima Al-Maqbali 2, Rajeev Aravindakshan 3
PMCID: PMC11809751  PMID: 39935995

Abstract

Background:

Cronobacter sakazakii is an opportunistic pathogen that mostly affects neonates, infants, and elderly people with weakened immune systems. No study has reported the frequency and antibiotic susceptibility patterns of C. sakazakii from Oman, and thus this study was conducted to fill this gap in the literature.

Materials and Methods:

This single-center retrospective study included C. sakazakii isolates identified from different clinical samples of patients treated at Sohar Hospital, Oman, between January 2017 and December 2023. Bacterial identification and antibiotic susceptibility testing were done using the VITEK II automated microbiological system in accordance with the Clinical Laboratory Standards Institute (CLSI) guidelines.

Results:

A total of 185 C. sakazakii isolates were included, most commonly from patients aged >60 years (42.7%) and <1 year (11.4%). C. sakazakii strains had high susceptibility (>80%) to most of the tested antibiotics; however, for beta-lactam antibiotics, it ranged from 0% to 50%. Approximately 26.5% of the strains were multidrug resistant. Independent risk factors for increased frequency of multidrug-resistant strains were urinary catheterization (P = 0.002), surgery (P = 0.021), previous antibiotic therapy (P = 0.047), and critical care unit admission (P = 0.048). About one-fifth of the patients experienced life-threatening C. sakazakii infections such as septicemia (15%) and pneumonia (4.7%). All deaths due to septicemia occurred in the >60 years (n = 12) and <1 year (n = 4) age groups.

Conclusions:

Cronobacter sakazakii isolates from the North Batinah region of Oman were most frequently isolated from elderly and infant patients and had high antibiotic susceptibility; however, the significant resistance against beta-lactams suggests their low effectiveness. The high number of multidrug-resistant strains coupled with the independent risk factors suggests the need for following stricter antibiotic stewardship protocols and infection control practices.

Keywords: Antimicrobial susceptibility, catheterization, Cronobacter sakazakii, Enterobacter sakazakii, infants, multidrug resistance, Oman, septicemia

INTRODUCTION

Cronobacter sakazakii, previously known as Enterobacter sakazakii, is a facultative anaerobic, Gram-negative flagellated bacterium belonging to the Enterobacteriaceae family.[1] C. sakazakii is classified as a foodborne pathogen and is found in contaminated food items, such as powdered milk infant formula (PMIF), dairy products, vegetables, cereals, herbs, and in contaminated feeding items such as breast pump equipment.[2,3,4,5,6] C. sakazakii has the ability to infect all age groups;[2,7] however, premature neonates, infants with low birth weight, and elderly people with weakened immune system, including cancer patients and who are on immunosuppressive therapy, are most vulnerable to severe form of the infection that includes septicemia, pneumonia, meningitis, necrotizing enterocolitis, and osteomyelitis.[7,8,9]

Cronobacter infections in infants aged <1 year are frequently associated with PMIF. Infants, particularly aged <2 months, are most likely to develop meningitis, which is associated with high mortality.[6] Furthermore, findings indicate acute, long-term, and chronic consequences in survivors of Cronobacter infection, including brain abscesses, quadriplegia, hydrocephalus, neurodevelopmental delays, and other neurological issues.[3] The global prevalence of C. sakazakii varies according to geographic region and sampling methodology.[3] Between January 2002 and July 2022, the US CDC documented 76 cases of severe Cronobacter infections in neonates, and in 2024, invasive Cronobacter infections in babies was classified as a nationally notifiable illnesses, mandating health professionals to report identified cases to help determine the actual incidence of this infection.[6] Globally, Cronobacter meningitis or bloodstream infections result in death in >40% of the cases in newborns, and in the United States, in >20% of the cases in infants.[6]

There are significant challenges arising in the treatment of C. sakazakii owing to their ability to acquire antibiotic resistance through biofilm formation and gene transfer mechanisms, and the rapid emergence of extremely drug-resistant strains such as carbapenem-resistant and extended-spectrum beta-lactamase (ESBL) producers.[10,11,12,13] Prevalence of C. sakazakii infections and their antibiotic susceptibility patterns have a geographic variation.[7,12,13,14,15,16] To the best of the authors’ knowledge, no study from Oman has reported the frequency of C. sakazakii infection and its antibiotic susceptibility patterns. The current study aimed at ascertaining the rate and clinical characteristics of C. sakazakii infection in patients treated at Sohar Hospital, Oman, from January 2017 to December 2023, with an emphasis on evaluating antibiotic susceptibility patterns, comorbidities, contributory variables, and the infection outcomes.

MATERIALS AND METHODS

This single-center, retrospective study was conducted at Sohar Hospital, which is the main secondary care center in the North Batinah region of Oman. C. sakazakii strains isolated from different clinical samples of patients treated at Sohar Hospital between January 2017 and December 2023 were included. All patients who were suspected of having C. sakazakii infection but had a negative bacterial culture report were excluded from the study. Patients with incomplete data were also excluded. Data pertinent to the patients, such as demographics, clinical characteristics, antibiotic susceptibility patterns, risk factors, and outcome of infection, were retrieved from the electronic health record system of the hospital.

The study received approval from the Research Ethical Review and Approval Committee of the Ministry of Health, Oman, and from the Institutional Review and Ethics Committee, College of Medicine and Health Sciences, National University of Science and Technology, Oman.

Bacterial identification and antibiotic susceptibility testing

Different clinical samples received at the microbiology laboratory at Sohar Hospital were cultured on blood agar and nutrient agar, as per the Clinical Laboratory Standards Institute (CLSI) guidelines.[17] Pathogen identification up to the species level was performed by the conventional identification method or the VITEK II automated microbiological system.[17] The antibiotic susceptibility of the isolated C. sakazakii was determined by the Kirby–Bauer disc diffusion method. The results of the antibiotic sensitivity were reported as sensitive, intermediate, and resistant, as per the CLSI guidelines. The tested antibiotics included ampicillin, amoxicillin, amoxicillin–clavulanic acid, amikacin, gentamicin, cefoxitin, cefuroxime, ceftriaxone, ceftazidime, cefotaxime, ciprofloxacin, imipenem, meropenem, piperacillin-tazobactam, nalidixic acid, and trimethoprim–sulfamethoxazole.

Broth microdilution and epsilometer tests were used to determine the minimum inhibitory concentrations of colistin and tigecycline. Multidrug-resistant (MDR) C. sakazakii were classified by non-susceptibility to at least one agent of three or more antimicrobial classes by standard susceptibility testing methods.[17] C. sakazakii strains that showed non-susceptibility to carbapenems by standard susceptibility testing methods (i.e., a minimum inhibitory concentration of ≥4 μg/mL for imipenem and/or meropenem) were categorized as carbapenem-resistant strains. C. sakazakii were initially screened for ESBL production by testing their resistance to ceftazidime. Further confirmation of ESBL production in the screen-positive strains was done using the double-disc synergy test and the CLSI confirmatory test.[17]

Statistical analysis

The data were processed in MS Excel and then analyzed using SPSS version 26 (SPSS Inc., IBM, Chicago, IL, United States). Categorical variables are presented as frequencies and proportions, and quantitative variables as mean and standard deviation (SD). For categorical variables, association was assessed using the chi-square test or Fisher’s exact test, with a significance level set at P < 0.05. Odds ratios were estimated with 95% confidence intervals for two-by-two tables of risk factors.

RESULTS

A total of 185 C. sakazakii isolates were obtained from 185 patients during the study period. Most patients were male (51.4%) and aged >60 years (42.7%), and had one or more comorbidities (69.2%). The most frequent comorbidities were cardiovascular diseases (73%), diabetes mellitus (41.6%), and renal diseases (28.6%). The most common surgical or medical interventions were antibiotic therapy within the past 2 months (40.5%), urinary catheterization (33.5%), and critical-care unit admission (23.2%). Isolates were most frequently recovered from urine (31%), pus and wound swabs (26%), and blood samples (25%) [Table 1].

Table 1.

Demographic characteristics of the included patients (N=185)

Variable n (%)
Gender
 Male 95 (51.4)
 Female 90 (48.6)
Age (years)
 0–1 21 (11.4)
 >1–30 18 (9.7)
 31–60 67 (36.2)
 >60 79 (42.7)
Clinical specimens
 Urine 57 (31)
 Pus and wound swab 49 (26)
 Blood 46 (25)
 Respiratory secretions 18 (10)
 Other samples 15 (8)
 Patients with one or more comorbidities 127 (69.2)
Comorbidities
 Diabetes mellitus 77 (41.6)
 Cardiovascular (HTN, IHD, others) 135 (73.0)
 Respiratory (COPD, asthma, others) 27 (14.6)
 Renal (ESRD, CKD, others) 53 (28.6)
 Neurological (CVA, others) 20 (10.8)
 Malignancy 8 (4.3)
Surgical or medical interventions
 Hemodialysis 41 (22.2)
 Mechanical ventilation 33 (17.8)
 Central venous catheterization 39 (21.1)
 Urinary catheterization 62 (33.5)
 Immunosuppressive therapy (chemotherapy, steroids) 15 (8.1)
 Previous antibiotic therapy (within 2 months) 73 (40.5)
 Critical care unit admission 43 (23.2)

HTN – Hypertension; IHD – Ischemic heart disease; COPD – Chronic obstructive pulmonary disease; ESRD – End-stage renal disease; CKD – Chronic kidney disease; CVA – Cerebrovascular accident

In terms of antibiotic susceptibility patterns, C. sakazakii demonstrated high susceptibility to gentamicin (85.1%), trimethoprim–sulfamethoxazole (82.8%), ciprofloxacin (81.4%), amikacin (80.1%), imipenem (78.6%), meropenem (78.2%), and piperacillin–tazobactam (78.1%). All strains were sensitive to tigecycline; however, 6.2% of the strains showed resistance to colistin. Beta-lactam antibiotic susceptibility levels ranged from 0% (ampicillin) to 52.2% (cefotaxime) [Table 2].

Table 2.

Antibiotic susceptibility patterns of Cronobacter sakazakii isolates

Antimicrobial agent Antibiotic susceptibility

Susceptible n (%) Resistant n (%)
Amikacin 75 (80.1) 18 (19.8)
Ampicillin 0 170 (100)
Amoxicillin-clavulanic acid 4 (2.3) 171 (97.7)
Cefotaxime 72 (52.2) 66 (47.8)
Cefuroxime 8 (3.4) 166 (96.6)
Ciprofloxacin 144 (81.4) 33 (18.6)
Colistin 15 (93.8) 1 (6.2)
Trimethoprim-sulfamethoxazole 140 (82.8) 29 (17.2)
Ceftriaxone 25 (31.3) 55 (68.7)
Ceftazidime 25 (31.6) 54 (68.4)
Gentamicin 149 (85.1) 26 (14.9)
Imipenem 66 (78.6) 18 (11.4)
Meropenem 68 (78.2) 19 (11.8)
Nalidixic acid 36 (63.2) 21 (36.8)
Piperacillin-tazobactam 99 (78.1) 28 (11.9)
Tigecycline 18 (100) 0

Figure 1 illustrates the yearly isolation of C. sakazakii and the MDR strains. Among the 185 isolates, 26.5% had resistance to multiple drugs, with 13.0%, 9.2%, and 4.3% being MDR, carbapenem-resistant, and ESBL strains, respectively. The frequency of isolation and number of MDR organisms (MDROs) strains was highest during the year 2020, which was the peak period of the COVID-19 pandemic in Oman.

Figure 1.

Figure 1

Yearly distribution of Cronobacter sakazakii isolates and multidrug-resistant organisms. MDROs – Multidrug-resistant organisms

A significant correlation was found between the emergence of MDR strains and urinary catheterization (P = 0.002), previous surgery (P = 0.021), previous antibiotic therapy (P = 0.047), and critical care unit admission (P = 0.048) [Table 3]. About one-fifth (20.5%) of the patients experienced life-threatening C. sakazakii infections such as septicemia (n = 28), pneumonia (9), and meningitis (1), and most of the cases were in infants and elderly patients. Of these, 16 patients died from bacterial septicemia and 2 from bacterial pneumonia. Infection with MDROs and the development of septicemia significantly raised the risk of mortality in the elderly (aged >60 years; P < 0.012) [Table 4]. All deaths due to septicemia occurred in the elderly (n = 12) and infants (n = 4).

Table 3.

Relationship between independent risk factors and emergence of drug-resistant Cronobacter sakazakii

Characteristic Yes (n=49), n (%) No (n=136), n (%) P OR (95% CI)
Diabetes mellitus
 Yes 23 (47) 57 (42) 0.5 1.22 (0.63–2.6)
 No 26 (53) 79 (58)
Renal
 Yes 15 (31) 35 (26) 0.8
 No 34 (69) 101 (74)
Respiratory
 Yes 8 (18.0) 14 (10) 0.5
 No 40 (82) 122 (90)
Neurological
 Yes 7 (14) 12 (8.8) 0.3 1.72 (0.63–4.66)
 No 42 (86) 124 (91)
Neoplasm
 Yes 3 (6.1) 6 (4.4) 0.7 1.41 (0.33–5.88)
 No 46 (94) 130 (96)
Critical care unit admission
 Yes 17 (35) 28 (21) 0.048 2.04 (0.99–4.21)
 No 32 (65) 108 (79)
Hemodialysis
 Yes 10 (20) 29 (21) 0.9 0.94 (0.42–2.12)
 No 39 (80) 107 (79)
Urinary catheterization
 Yes 26 (53) 38 (28) 0.002 2.91 (1.48–5.72)
 No 23 (47) 98 (72)
Surgery
 Yes 25 (51) 44 (32) 0.021 2.17 (1.11–4.23)
 No 24 (49) 92 (68)
Previous antibiotic therapy (within 2 months)
 Yes 26 (53) 50 (37) 0.047 1.94 (1.00–3.76)
 No 23 (47) 86 (63)

CI – Confidence interval; OR – Odds ratio

Table 4.

Relationship between septicemia and multidrug-resistant organisms with mortality

Characteristics Septicemia (n=28), n (%) Others (n=157), n (%) OR P
Age (>60 years) 18 (64) 61 (39) 2.83 (1.22–6.54) 0.012
Death 12 (60) 8 (40) 13.25 (3.82–45.33) <0.001
MDRO identified 11 (47.8) 12 (52.2) 6.41 (2.05–20.03) <0.001
Age (≤1 year) 6 (28.6) 15 (71.4) 2.58 (0.91–7.36) 0.06
Death 4 (66.7) 2 (33.3) 13.00 (1.35–124.3) 0.014
MDRO identified 1 (100) 0 Not calculated 0.10

MDRO – Multidrug-resistant organism; OR – Odd ratio

DISCUSSION

C. sakazakii is an emerging and opportunistic pathogen capable of causing a wide range of infections.[18] Although the incidence of C. sakazakii is low, its diversity, virulence, higher mortality rates, emergence of drug resistance, particularly multidrug resistance, and potential for transmission necessitate attention to prevent its spread.[19] In the current study, critical care admission, previous antibiotic therapy, and urinary catheterization were found to be independent risk factors for the increased frequency of MDRO strains.

C. sakazakii were isolated almost equally in male and female subjects. Further, most isolates (42.7%) were found in patients aged >60 years, with most having one or more comorbidities, suggesting weakened immune system. In addition, the second highest proportion of isolates were from infants. These findings are in accordance with similar studies conducted worldwide, wherein C. sakazakii infection have been reported to be highest in newborns with underdeveloped immune systems, likely due to being born prematurely or with low birth weight, and older individuals with some level of declining immunity due to various comorbidities.[3,18,19,20,21,22,23,24]

Most studies have reported Cronobacter infections in infants, with only a few documenting these infections in adults.[23,24] The underreporting of Cronobacter infections in adults could possibly be attributed to their rarity and the mild nature of the infections in healthy people. Furthermore, risk factors for the transmission of infection in adults are poorly understood.[23] Routine and systematic surveillance, together with specific research, are crucial for identifying and understanding the reservoirs of Cronobacter infection and sources of transmission in adults.[24] In terms of the source of infection, the current study was unable to determine the same due to the retrospective study design and missing information. In general, contaminated PMIFs are frequently identified as the source of newborn infection. However, C. sakazakii can be also found in a variety of food sources, including cereals, herbs, fruits, meat, vegetables, rehydrated powdered milk, and ready-to-eat foods, as well as through contamination of breast pumps, enteral feeding tubes, and baby food items in dairy manufacturing facilities and utensils such as spoons and blenders used for preparing baby food in hospitals and homes.[25,26] Future studies in Oman must emphasize at determining the sources of Cronobacter infection to formulate effective preventive strategies.

C. sakazakii is notably associated with infections such as bloodstream infection, including septicemia, urinary tract infections, skin and soft tissue infections, meningitis, and respiratory tract infections, including pneumonia.[23,25,27] In line with this, C. sakazakii was most frequently isolated in the present study from urine samples, pus and wound swabs, blood, and respiratory secretions. Most of our patients were exposed to medical or surgical interventions. Use of contaminated hospital instruments and equipment, such as catheters and ventilators, is an important source of healthcare-associated infection for Enterobacterales, the family to which C. sakazakii belongs.[28,29]

C. sakazakii are susceptible to most of the commonly used antibiotics. However, excessive, and improper use of antibiotics in humans, animals, and crops has caused the recent development of MDR bacteria, which can result in treatment failure, prolonged illness, and increased risk of mortality.[4,30,31] Antimicrobial resistance patterns of C. sakazakii differ across geographic regions due to variations in the antibiotic prescribing policy and adherence to antibiotic stewardship.[15,16] Csorba et al.[32] documented that all C. sakazakii strains found in milk powder were sensitive to all tested antimicrobials and showed no signs of multidrug resistance. A study by Pakbin et al.[4] revealed that C. sakazakii isolates were highly resistant to amoxicillin–clavulanic acid, amoxicillin, ampicillin, cefoxitin, cefepime, erythromycin, ceftriaxone, ciprofloxacin, and chloramphenicol and highly susceptible to gentamicin, tetracycline, norfloxacin, and azithromycin. In another study, Li et al.,[14] found that all C. sakazakii strains demonstrated susceptibility to ampicillin–sulbactam, imipenem, aztreonam, and trimethoprim–sulfamethoxazole, and showed maximum resistance to cephalothin. Consistent with these results, in our study, C. sakazakii showed high susceptibility (80%–85%) to amikacin, gentamicin, trimethoprim-sulfamethoxazole, ciprofloxacin, imipenem, meropenem, and piperacillin-tazobactam, indicating these antibiotics as preferred choices for the initial treatment. Further, Cronobacter strains exhibited significant resistance (50%–100%) to beta-lactam antibiotics such as amoxicillin, amoxicillin-clavulanic acid, ceftriaxone, ceftazidime, and cefuroxime, making them unsuitable for treating these infections.

In our study, a small percentage of C. sakazakii strains were identified as MDROs, such as MDR, carbapenem-resistant, and ESBL producing strains, with the highest incidence in 2020, coinciding with the peak of the COVID-19 pandemic in Oman. The sharp increase in the frequency and emergence of MDR strains in 2020 is partially attributed to the widespread antibiotic prescribing pattern by physicians who were uncertain about the diagnosis of COVID-19 during the early phase of the pandemic. Bloodstream infection with MDR pathogens often leads to septicemia and related complications. Moreover, the risk of death increases with the development of septicemia, particularly in immune-suppressed patients.[33] Of note, there was a decline in the frequency of MDROs in our hospital between 2017 and 2023, which may largely be due to the recent introduction of an antibiotic stewardship program and a continuous antibiotic prescription surveillance system at the hospital.

In our study, we found a significant correlation between the increased number of deaths due to septicemia in immune-suppressed individuals including neonates, infants, and the elderly. Previous studies have firmly established this positive correlation among other Enterobacteriaceae organisms.[34,35] However, no previous study has been conducted to demonstrate an association between the increased frequency of MDR C. sakazakii and the hospital-related independent risk factors such as critical care admission, urinary catheterization, surgery, and previous antibiotic therapy for transmission of MDRO infection and mortality in adults. Therefore, future research should emphasize on establishing a correlation between independent risk factors and the emergence and dissemination of MDR C. sakazakii strains and the outcome of infection.

Limitations

Our study has several limitations. First, because of the retrospective study design, some of the information related to the source of infection and risk factors in infants, such as prematurity and low birth weight, could not be explored. Therefore, we could not relate their role as sources and risk factors for C. sakazakii infection. Second, biochemical test panels and VITEK identification systems are less reliable for an accurate identification of Cronobacter up to the species level, and thus future studies should be conducted with matrix-assisted laser desorption ionization time-of-flight mass spectrometry assays and molecular studies, which have higher accuracy.[20,21,22,23] Third, the exact cause of death and confounding factors of mortality were not reported in a few cases. Fourth, the study did not determine the antimicrobial resistance genes in MDR, ESBL, and carbapenem-resistant strains. Fifth, most of our patients were exposed to medical or surgical interventions; however, there was a lack of information about how these interventions contributed to Cronobacter transmission to the patients. Finally, the study was a single-center study with a small sample size, thereby limiting generalizability and requiring larger multi-center studies to validate these findings.

CONCLUSIONS

This study found that in the North Batinah region of Oman, Cronobacter sakazakii isolates were most frequently isolated from elderly and infant patients and had high susceptibility (>80%) to most of the tested antibiotics but exhibited significant resistance to beta-lactam antibiotics (50%–100%). In addition, about one-fourth of the strains were multidrug resistant, and the independent risk factors for increased frequency of multidrug-resistant strains were previous antibiotic therapy, urinary catheterization, and surgery. Further, large-scale studies using higher accuracy assays and molecular studies are required to validate the findings of this study.

Ethical considerations

The study received approval from the Research Ethical Review and Approval Committee of the Ministry of Health, Oman, and from the Institutional Review and Ethics Committee, College of Medicine and Health Sciences, National University of Science and Technology, Oman (Approval no.: MOH/CSR/23/27674; date: November 26, 2023). Requirement for patient consent was waived owing to the study design. The study adhered to the principles of the Declaration of Helsinki, 2013.

Peer review

This article was peer-reviewed by three independent and anonymous reviewers.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author contributions

Conceptualization: M.B.S., V.N.; Methodology: M.B.S., O.M.S.A., M.M.S.A., I.M.A.A., Z.M.A.H., and S.A.; Data analysis: R.A.; Writing–original draft preparation: M.B.S.; Writing – review and editing: V.N.; Supervision: M.B.S.

All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

There are no conflicts of interest.

Acknowledgements

Authors express their gratitude to Mr. Jaya Prasad, Information and Technology Department, Sohar Hospital, and all the microbiology laboratory staff of the hospital for their assistance in data collection.

Funding Statement

Nil.

REFERENCES

  • 1.Holý O, Alsonosi A, Hochel I, Röderová M, Zatloukalová S, Mlynárčik P, et al. Antibiotic susceptibility of Cronobacter spp. Isolated from clinical samples. Pol J Microbiol. 2019;68:5–14. doi: 10.21307/pjm-2019-001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mazi IM, Onyeaka H, Nnaji ND. Foodborne pathogens in Africa: Understanding Cronobacter sakazakii. Public Health Chall. 2023;2:e53. [Google Scholar]
  • 3.Ekundayo TC, Ijabadeniyi OA. Global and regional prevalence of Cronobacter sakazakii in powdered milk and flour. Sci Rep. 2024;14:6865. doi: 10.1038/s41598-024-57586-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Pakbin B, Mahmoudi R, Mousavi S, Allahyari S, Amani Z, Peymani A, et al. Genotypic and antimicrobial resistance characterizations of Cronobacter sakazakii isolated from powdered milk infant formula: A comparison between domestic and imported products. Food Sci Nutr. 2020;8:6708–17. doi: 10.1002/fsn3.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Aly MA, Domig KJ, Kneifel W, Reimhult E. Whole genome sequencing-based comparison of food isolates of Cronobacter sakazakii . Front Microbiol. 2019;10:1464. doi: 10.3389/fmicb.2019.01464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Centers for Disease Control and Prevention. About Cronobacter. [[Last accessed 2024 May 13]]. Available from: https://www.cdc.gov/cronobacter/about/index.html .
  • 7.Liu S, Song D, Liu B, Dong K, Jiang Y, Man C, et al. Transcriptomic analyses to unravel Cronobacter sakazakii resistance pathways. Foods. 2024;13:2786. doi: 10.3390/foods13172786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Elkhawaga AA, Hetta HF, Osman NS, Hosni A, El-Mokhtar MA. Emergence of Cronobacter sakazakii in cases of neonatal sepsis in Upper Egypt: First report in North Africa. Front Microbiol. 2020;11:215. doi: 10.3389/fmicb.2020.00215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Song X, Teng H, Chen L, Kim M. Cronobacter species in powdered infant formula and their detection methods. Korean J Food Sci Anim Resour. 2018;38:376–90. doi: 10.5851/kosfa.2018.38.2.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Cheng C, Yan X, Liu B, Jiang T, Zhou Z, Guo F, et al. SdiA enhanced the drug resistance of Cronobacter sakazakii and suppressed its motility, adhesion and biofilm formation. Front Microbiol. 2022;13:901912. doi: 10.3389/fmicb.2022.901912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Khademi F, Vaez H, Neyestani Z, Sahebkar A. Prevalence of ESBL-producing Enterobacter Species resistant to carbapenems in Iran: A systematic review and meta-analysis. Int J Microbiol. 2022;2022:8367365. doi: 10.1155/2022/8367365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Jean SS, Lee WS, Hsueh PR SMART Asia-Pacific Group. Ertapenem non-susceptibility and independent predictors of the carbapenemase production among the Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Infect Drug Resist. 2018;11:1881–91. doi: 10.2147/IDR.S181085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Henry M, Fouladkhah A. Outbreak history, biofilm formation, and preventive measures for control of Cronobacter sakazakii in infant formula and infant care settings. Microorganisms. 2019;7:77. doi: 10.3390/microorganisms7030077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Li C, Zeng H, Zhang J, He W, Ling N, Chen M, et al. Prevalence, antibiotic susceptibility, and molecular characterization of Cronobacter spp. isolated from edible mushrooms in China. Front Microbiol. 2019;10:283. doi: 10.3389/fmicb.2019.00283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zeng H, Lei T, He W, Zhang J, Liang B, Li C, et al. Novel multidrug-resistant Cronobacter sakazakii causing meningitis in neonate, China, 2015. Emerg Infect Dis. 2018;24:2121–4. doi: 10.3201/eid2411.180718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Fei P, Jiang Y, Jiang Y, Yuan X, Yang T, Chen J, et al. Prevalence, molecular characterization, and antibiotic susceptibility of Cronobacter sakazakii isolates from powdered infant formula collected from Chinese retail markets. Front Microbiol. 2017;8:2026. doi: 10.3389/fmicb.2017.02026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Clinical and Laboratory Standards Institute. Clinical and Laboratory Standards for Antimicrobial Susceptibility Testing. 28th ed. Wayne, PA: Standards Institute; 2018. Performance CLSI Supplement M100. [Google Scholar]
  • 18.Polat YemişG, Delaquis P. Natural compounds with antibacterial activity against Cronobacter spp. in powdered infant formula: A review. Front Nutr. 2020;7:595964. doi: 10.3389/fnut.2020.595964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kumar A, Vaiyapuri M, Mothadaka MP. Antimicrobial resistance in Cronobacter sakazakii. In: Mothadaka MP, Vaiyapuri M, Rao Badireddy M, Nagarajrao Ravishankar C, Bhatia R, Jena J, editors. Handbook on Antimicrobial Resistance. Singapore: Springer; 2023. [Google Scholar]
  • 20.Lee IP, Andam CP. Pan-genome diversification and recombination in Cronobacter sakazakii, an opportunistic pathogen in neonates, and insights to its xerotolerant lifestyle. BMC Microbiol. 2019;19:306. doi: 10.1186/s12866-019-1664-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mousavi ZE, Hunt K, Koolman L, Butler F, Fanning S. Cronobacter species in the built food production environment: A review on persistence, pathogenicity, regulation and detection methods. Microorganisms. 2023;11:1379. doi: 10.3390/microorganisms11061379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Odeyemi OA, Sani NA. The prevention of Cronobacter infections in hospital neonatal intensive care units. J Infect Public Health. 2016;9:110–2. doi: 10.1016/j.jiph.2015.06.012. [DOI] [PubMed] [Google Scholar]
  • 23.Hayashi S, Takinami Y, Watari T. Urinary tract infection caused by Cronobacter sakazakii . Cureus. 2021;13:e15780. doi: 10.7759/cureus.15780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Lepuschitz S, Ruppitsch W, Pekard-Amenitsch S, Forsythe SJ, Cormican M, Mach RL, et al. Multicenter study of Cronobacter sakazakii infections in humans, Europe, 2017. Emerg Infect Dis. 2019;25:515–22. doi: 10.3201/eid2503.181652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Parra-Flores J, Flores-Soto F, Flores-Balboa C, Alarcón-Lavín MP, Cabal-Rosel A, Daza-Prieto B, et al. Characterization of Cronobacter sakazakii and Cronobacter malonaticus strains isolated from powdered dairy products intended for consumption by adults and older adults. Microorganisms. 2023;11:2841. doi: 10.3390/microorganisms11122841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Haston JC, Miko S, Cope JR, McKeel H, Walters C, Joseph LA, et al. Cronobacter sakazakii infections in two infants linked to powdered infant formula and breast pump equipment –United States, 2021 and 2022. MMWR Morb Mortal Wkly Rep. 2023;72:223–6. doi: 10.15585/mmwr.mm7209a2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sahra S, Jahangir A, Mobarakai N, Glaser A, Jahangir A, Sharif MA. First case report of acute cholangitis secondary to Cronobacter sakazakii. BMC Infect Dis. 2021;21:493. doi: 10.1186/s12879-021-06195-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Owusu E, Asane FW, Bediako-Bowan AA, Afutu E. Bacterial contamination of surgical instruments used at the surgery department of a major teaching hospital in a resource-limited country: An observational study. Diseases. 2022;10:81. doi: 10.3390/diseases10040081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Holý O, Forsythe S. Cronobacter spp. as emerging causes of healthcare-associated infection. J Hosp Infect. 2014;86:169–77. doi: 10.1016/j.jhin.2013.09.011. [DOI] [PubMed] [Google Scholar]
  • 30.Sannathimmappa MB, Nambiar V, Aravindakshan R. Antibiotics at the crossroads –Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance? J Educ Health Promot. 2021;10:438. doi: 10.4103/jehp.jehp_557_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sannathimmappa MB, Nambiar V, Aravindakshan R. A cross-sectional study to evaluate the knowledge and attitude of medical students concerning antibiotic usage and antimicrobial resistance. Int J Acad Med. 2021;7:113–9. [Google Scholar]
  • 32.Csorba C, Pajić M, Blagojević B, Forsythe S, Radinović M, Velebit B. Prevalence, characterization, and antibiotic susceptibility of Cronobacter spp. in a milk powder processing environment: The first reported case in Serbia. Food Sci Nutr. 2022;10:554–63. doi: 10.1002/fsn3.2681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Di Franco S, Alfieri A, Pace MC, Sansone P, Pota V, Fittipaldi C, et al. Blood stream infections from MDR bacteria. Life (Basel) 2021;11:575. doi: 10.3390/life11060575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Perez-Palacios P, Girlich D, Soraa N, Lamrani A, Maoulainine FM, Bennaoui F, et al. Multidrug-resistant Enterobacterales responsible for septicaemia in a neonatal intensive care unit in Morocco. J Glob Antimicrob Resist. 2023;33:208–17. doi: 10.1016/j.jgar.2023.02.011. [DOI] [PubMed] [Google Scholar]
  • 35.Tompkins K, Juliano JJ, van Duin D. Antimicrobial resistance in Enterobacterales and its contribution to sepsis in Sub-Saharan Africa. Front Med (Lausanne) 2021;8:615649. doi: 10.3389/fmed.2021.615649. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.


Articles from Saudi Journal of Medicine & Medical Sciences are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES